Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

被引:12
作者
Overbeek, Jetty A. [1 ,2 ]
Heintjes, Edith M. [1 ]
Huisman, Eline L. [3 ]
Tikkanen, Christian K. [4 ]
van Diermen, Arnout W. [3 ]
Penning-van Beest, Fernie J. A. [1 ]
Herings, Ron M. C. [1 ,5 ]
机构
[1] PHARMO Inst Drug Outcomes Res, Deventerlaan 30-40, NL-3528 AE Utrecht, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands
[3] Novo Nordisk Farma BV, Alphen Aan Den Rijn, Netherlands
[4] Novo Nordisk Reg Europe Pharmaceut AS, Copenhagen, Denmark
[5] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
liraglutide; obese; real-world data; T2DM; the Netherlands; RANDOMIZED CONTROLLED-TRIALS; CARDIOVASCULAR EVENTS; EUROPEAN ASSOCIATION; POSITION STATEMENT; ECONOMIC OUTCOMES; ALL-CAUSE; COMPLICATIONS; MELLITUS; MANAGEMENT; MORTALITY;
D O I
10.1111/dom.13335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To compare real-world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic therapy and then initiated a first injectable therapy with liraglutide or basal insulin. Patients and methods: This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network. Adult obese (body mass index [BMI] >= 35 kg/m(2)) patients with T2DM with >= 2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline during 12 months of follow-up. The secondary endpoints were the changes in weight, BMI and cardiovascular risk factors from baseline. Clinical data were analysed using descriptive statistics and compared using mixed models for repeated measures. Results: Obese patients with T2DM (N = 1157) in each treatment group were matched (liraglutide cohort, n = 544; BOT cohort, n = 613). From 3 months onwards, glycaemic control improved in both cohorts but improved significantly more with liraglutide than with BOT (12 months: -12.2 mmol/mol vs -8.8 mmol/mol; P = .0053). In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: -6.0 kg vs -1.6 kg and - 2.1 kg/m(2) vs -0.5 kg/m(2), respectively; P < .0001 for both). No significant differences were seen in changes in cardiovascular risk factors. Conclusions: The results of this real-world study in matched obese patients with T2DM showed that liraglutide was more effective than BOT for HbA1c control and weight/BMI reductions. Patients were more likely to maintain glycaemic control over time after initiating liraglutide than after initiating BOT.
引用
收藏
页码:2093 / 2102
页数:10
相关论文
共 32 条
[1]   A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients [J].
Abd El Aziz, Mirna S. ;
Kahle, Melanie ;
Meier, Juris J. ;
Nauck, Michael A. .
DIABETES OBESITY & METABOLISM, 2017, 19 (02) :216-227
[2]  
[Anonymous], 2013, Huisarts Wetenschap
[3]   Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes [J].
Anyanwagu, Uchenna ;
Mamza, Jil ;
Mehta, Rajnikant ;
Donnelly, Richard ;
Idris, Iskandar .
HEART, 2016, 102 (19) :1581-1587
[4]   Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data [J].
Ashbeck, Erin L. ;
Bell, Melanie L. .
BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16
[5]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[6]   Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140-2147 [J].
Bergenstal, Richard M. ;
Rosenstock, Julio ;
Arakaki, Richard F. ;
Prince, Melvin J. ;
Qu, Yongming ;
Sinha, Vikram P. ;
Howey, Daniel C. ;
Jacober, Scott J. .
DIABETES CARE, 2013, 36 (07) :E107-+
[7]   Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study [J].
Buysman, Erin K. ;
Liu, Fang ;
Hammer, Mette ;
Langer, Jakob .
ADVANCES IN THERAPY, 2015, 32 (04) :341-355
[8]   Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria [J].
Dimitrova, Maria ;
Doneva, Miglena ;
Valov, Vasil ;
Yordanova, Stanislava ;
Manova, Manoela ;
Savova, Alexandra ;
Mitov, Konstantin ;
Petrova, Guenka ;
Petkova, Valentina ;
Czech, Marcin .
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2015, 29 (04) :805-813
[9]   Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania [J].
Domeikiene, Aukse ;
Vaivadaite, Justina ;
Ivanauskiene, Rugile ;
Padaiga, Zilvinas .
MEDICINA-LITHUANIA, 2014, 50 (01) :54-60
[10]   Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients [J].
Eeg-Olofsson, K. ;
Cederholm, J. ;
Nilsson, P. M. ;
Zethelius, B. ;
Nunez, L. ;
Gudbjoernsdottir, S. ;
Eliasson, B. .
DIABETOLOGIA, 2009, 52 (01) :65-73